Vitravir 400 mg, 50 mg Tablet

Vitravir 400 mg, 50 mg Tablet

S4
PDF Leaflet Revision Date: 20 September 2022

API: Darunavir And Ritonavir | Company: Mylan

Clinical Summary

Quick overview from the medicine insert

Indication

Treatment of HIV infection in antiretroviral treatment experienced adult patients.

Dosage (summary)

Two tablets once daily with food.

Special Populations

  • Elderly
  • Renal impairment
  • Hepatic impairment

Pregnancy & Breastfeeding

Contraindicated in pregnancy and lactation; safety not established.

Key Drug Interactions

  • CYP3A inhibitors
  • Rifampicin
  • St. John's Wort
  • Antidysrhythmics
  • Anticonvulsants

Contraindications

  • Hypersensitivity to darunavir or ritonavir
  • Severe hepatic impairment

Common side effects

  • Rash
  • Diarrhea
  • Nausea
  • Fatigue
  • Hyperglycemia

Counselling Points

  • Take with food
  • Monitor for skin reactions
  • Regular liver function tests
  • Avoid certain medications

Serious warnings

  • Severe skin reactions
  • Hepatotoxicity
  • Pancreatitis
  • Immune reconstitution syndrome
Important Disclaimer

The Vitravir 400 mg, 50 mg Tablet professional information leaflet below is the property of Mylan and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

Healthcare Professionals Only

This content is for registered healthcare professionals

Sign in or create a free account to read the full package insert.

Free for HPCSA-registered professionals. Powered by Medinsert.

Successfully Stashed! 💊

This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

View My Favourites